DDInter1233 DDInter224
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR ABL ratio on an international scale, with bosutinib treatment.
Mitotane {u} (Compound) upregulates {v} (Gene) AGR2
AGR2 {u} (Gene) is upregulated by {v} (Compound) Bosutinib
Mitotane {u} (Compound) downregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is upregulated by {v} (Compound) Bosutinib
Mitotane {u} (Compound) causes {v} (Side Effect) Urinary tract disorder
Urinary tract disorder {u} (Side Effect) is caused by {v} (Compound) Bosutinib
Mitotane {u} (Compound) upregulates {v} (Gene) AGR2
AGR2 {u} (Gene) is regulated by {v} (Gene) CDK2
CDK2 {u} (Gene) is bound by {v} (Compound) Bosutinib
Mitotane {u} (Compound) downregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) regulates {v} (Gene) CSNK1E
CSNK1E {u} (Gene) is bound by {v} (Compound) Bosutinib
Mitotane {u} (Compound) causes {v} (Side Effect) Urinary tract disorder
Urinary tract disorder {u} (Side Effect) is caused by {v} (Compound) Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Bosutinib
Mitotane {u} (Compound) causes {v} (Side Effect) Dysgeusia
Dysgeusia {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bosutinib
Mitotane {u} (Compound) causes {v} (Side Effect) Gastrointestinal toxicity
Gastrointestinal toxicity {u} (Side Effect) is caused by {v} (Compound) Methotrexate
Methotrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Bisacodyl
Bisacodyl {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Mitotane {u} (Compound) downregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is regulated by {v} (Gene) ALK
ALK {u} (Gene) is bound by {v} (Compound) Bosutinib
Mitotane (Compound) upregulates AGR2 (Gene) and AGR2 (Gene) is upregulated by Bosutinib (Compound)
Mitotane (Compound) downregulates HMGCR (Gene) and HMGCR (Gene) is upregulated by Bosutinib (Compound)
Mitotane (Compound) causes Urinary tract disorder (Side Effect) and Urinary tract disorder (Side Effect) is caused by Bosutinib (Compound)
Mitotane (Compound) upregulates AGR2 (Gene) and AGR2 (Gene) is regulated by CDK2 (Gene) and CDK2 (Gene) is bound by Bosutinib (Compound)
Mitotane (Compound) downregulates HMGCR (Gene) and HMGCR (Gene) regulates CSNK1E (Gene) and CSNK1E (Gene) is bound by Bosutinib (Compound)
Mitotane (Compound) causes Urinary tract disorder (Side Effect) and Urinary tract disorder (Side Effect) is caused by Gefitinib (Compound) and Gefitinib (Compound) resembles Bosutinib (Compound)
Mitotane (Compound) causes Dysgeusia (Side Effect) and Dysgeusia (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bosutinib
Mitotane (Compound) causes Gastrointestinal toxicity (Side Effect) and Gastrointestinal toxicity (Side Effect) is caused by Methotrexate (Compound) and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Mitotane (Compound) resembles Carbinoxamine (Compound) and Carbinoxamine (Compound) resembles Bisacodyl (Compound) and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Mitotane (Compound) downregulates HMGCR (Gene) and HMGCR (Gene) is regulated by ALK (Gene) and ALK (Gene) is bound by Bosutinib (Compound)